Related Experiment Video
Updated: Oct 8, 2025
Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
Published on: November 8, 2024
Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled
Lawrence F Eichenfield1,2,3,4,5,6, Pearl Kwong1,2,3,4,5,6, Mercedes E Gonzalez1,2,3,4,5,6
1Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California.
Trial Registration:
>ClinicalTrials.gov identifier nos. NCT03377790 (for CAMP-1) and NCT03377803 (for CAMP-2).
Background:
VP-102 is drug-device combination product containing cantharidin (0.7% w/v) and has undergone Phase III clinical trials for the treatment of molluscum contagiosum (molluscum). Efficacy and safety may differ by body region due to variable skin anatomy.
Objective:
We investigated the pooled safety and efficacy of VP-102 by affected body region.
Methods:
Individuals at least two years of age with molluscum were randomized to topical VP-102 or vehicle once every 21 days until clear (maximum of four applications). Participants were assigned to body region groups where lesions were present at baseline. Body region lesion counts were recorded at each visit. Efficacy was measured by the percentage of participants with complete clearance of lesions by region. Pre-specified adverse events (AEs) were analyzed for those treated in the region on that visit.
Results:
Participants had a mean of two regions affected at baseline. Complete clearance was significantly higher in the VP-102-treated group than with vehicle application in all regions at the last visit (P<0.01 for each region). The incidence of pre-specified AEs was consistent across regions. However, these analyses were post hoc, and individual lesions were not tracked for efficacy.
Conclusion:
VP-102 treatment shows consistent safety and efficacy across molluscum body regions.
